-
Je něco špatně v tomto záznamu ?
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
D. Rožková, H. Tišerová, J. Fučíková, J. Lašťovička, M. Podrazil, H. Ulčová, V. Budínský, J. Prausová, Z. Linke, I. Minárik, A. Šedivá, R. Špíšek, J. Bartůňková
Jazyk angličtina Země Spojené státy americké
NLK
ScienceDirect (archiv)
od 1999-01-01 do 2009-12-31
- MeSH
- adenokarcinom sekundární terapie MeSH
- antitumorózní látky terapeutické užití MeSH
- financování organizované MeSH
- imunoterapie metody MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- nádory kostí sekundární terapie MeSH
- nádory prostaty patologie terapie MeSH
- nádory závislé na hormonech sekundární terapie MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.
- 000
- 03905naa 2200517 a 4500
- 001
- bmc11009458
- 003
- CZ-PrNML
- 005
- 20121102102629.0
- 008
- 110510s2009 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rožková, Daniela, $d 1979- $7 xx0118296
- 245 10
- $a FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer / $c D. Rožková, H. Tišerová, J. Fučíková, J. Lašťovička, M. Podrazil, H. Ulčová, V. Budínský, J. Prausová, Z. Linke, I. Minárik, A. Šedivá, R. Špíšek, J. Bartůňková
- 314 __
- $a Institute of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic.
- 520 9_
- $a Immunotherapy has emerged as another treatment modality in cancer. The goal of immunotherapy in advanced cancer patients does not have to be the complete eradication of tumor cells but rather the restoration of a dynamic balance between tumor cells and the immune response. Appropriate combination of tumor mass reduction (by surgery and/or chemotherapy) and neutralization of tumor-induced immunosuppression might set the right conditions for the induction of anti-tumor immune response by active immunotherapy. We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis. More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them. In half of these patients, DC immunotherapy resulted in transient clinical responses. Tregs, among other factors, potently inhibit tumor-specific T cells. Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo. Because of the high frequency of circulating Tregs in our patients, we first administered metronomic cyclophosphamide. After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells. In accordance with the principles of combined immunotherapy, we continued palliative chemotherapy with docetaxel to reduce the tumor cell burden. DC-based vaccination induced prostate cancer cell-specific immune response. Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a adenokarcinom $x sekundární $x terapie $7 D000230
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a nádory kostí $x sekundární $x terapie $7 D001859
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádory závislé na hormonech $x sekundární $x terapie $7 D009376
- 650 _2
- $a nádory prostaty $x patologie $x terapie $7 D011471
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Hromádková, Hana, $d 1982- $7 xx0118299
- 700 1_
- $a Fučíková, Jitka, $d 1983- $7 xx0116819
- 700 1_
- $a Lašťovička, Jan, $d 1956- $7 xx0064149
- 700 1_
- $a Podrazil, Michal, $d 1978- $7 xx0118288
- 700 1_
- $a Ulčová, Hana, $d 1981- $7 xx0118298
- 700 1_
- $a Budinský, Vít, $d 1980- $7 xx0118293
- 700 1_
- $a Prausová, Jana, $d 1956- $7 xx0025145
- 700 1_
- $a Linke, Zdeněk $7 xx0139978
- 700 1_
- $a Minárik, Ivo. $7 xx0227806
- 700 1_
- $a Šedivá, Anna, $d 1955- $7 xx0000191
- 700 1_
- $a Špíšek, Radek, $d 1975- $7 nlk20030145288
- 700 1_
- $a Bartůňková, Jiřina, $d 1958- $7 jn20000400093
- 773 0_
- $t Clinical Immunology $w MED00005218 $g Roč. 131, č. 1 (2009), s. 1-10
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110513105406 $b ABA008
- 991 __
- $a 20121102102634 $b ABA008
- 999 __
- $a ok $b bmc $g 839020 $s 702843
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00005218 $b 131 $c 1 $d 1-10 $m Clinical immunology $n Clin Immunol
- LZP __
- $a 2011-2B09/jvme